Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will present final data from its Phase 1/1b trial of soquelitinib in relapsed/refractory T cell lymphomas at the 67th American Society of Hematology Annual Meeting & Exposition.
The oral presentation is scheduled for December 8, 2025, Session 625 (T Cell, NK Cell, or NK/T Cell Lymphomas), with a presentation slot from 11:15 AM–11:30 AM (session 10:30 AM–12:00 PM). Publication number is 778; the title reports final Phase 1 results for soquelitinib (SQL), an ITK inhibitor for R/R T cell lymphomas.
Positive
- None.
Negative
- None.
News Market Reaction – CRVS
On the day this news was published, CRVS declined 4.48%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $28M from the company's valuation, bringing the market cap to $599.09M at that time.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 6-9, 2025 in Orlando, FL.
Details regarding the oral presentation are as follows:
Session Name: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell Lymphoma
Session Date: December 8, 2025
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 11:15 AM - 11:30 AM
Publication Number: 778
Title: Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is now in a registration Phase 3 clinical trial for relapsed/refractory T cell lymphoma and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus Pharmaceuticals (CRVS) present soquelitinib Phase 1/1b final data at ASH 2025?
What is the ASH 2025 session and publication number for CRVS soquelitinib data?
What will Corvus (CRVS) present about soquelitinib at ASH 2025?
Where and when is the 67th ASH Annual Meeting where CRVS will present?
How long is the Corvus (CRVS) presentation slot for soquelitinib at ASH?
What is soquelitinib (SQL) as described in the ASH 2025 listing for CRVS?
